Dipexium Pharmaceuticalsが日本のLocilex(R)特許発行を発表
Dipexium Pharmaceuticalsが日本のLocilex(R)特許発行を発表
AsiaNet 63894 (0381)
【ニューヨーク2016年3月28日PR Newswire=共同通信JBN】後期段階医薬品会社で、薬効範囲の広い新局所抗微生物ペプチド、Locilex(R)(一般名ペキシガナン・クリーム0.8%)の開発、商業化に集中しているDipexium Pharmaceuticals, Inc. (Nasdaq: DPRX)は28日、日本政府がLocilexの特許を発行したと発表した。特許クレームは局所クリームとして配合された抗微生物ペプチドであるLocilexの新たな配合を対象にしている。発行された特許は2033年6月が期限である。
Dipexiumのデービッド・P・ルーシ社長兼最高経営責任者(CEO)は「世界第3の医薬品市場である日本でLocilexの特許を受けられたのはうれしい。わが社はその他の主要国際市場で追加的なLocilex特許が発行されることを期待しており、それによって全世界でLocilexの商業的実行可能性を確立し続けることが可能になる」と述べた。
▽Dipexium Pharmaceuticals, Inc.について
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX)は後期段階医薬品会社で、薬効範囲の広い新局所抗微生物ペプチド、Locilex(一般名ペキシガナン・クリーム0.8%)の開発、商業化に集中している。当初、Locilexは軽度に化のうした糖尿病性足部潰瘍の治療を標的としていた。また入手可能な臨床、微生物学的データのまとめに基づいて、Locilexは化のうした床ずれ、やけど、手術の傷、メチシリン耐性黄色ブドウ球菌(MRSA)の鼻への広がりを含むその他の軽度から中程度の皮膚および皮膚組織の化のうを治療するための有望な製品候補ともみられている。
▽問い合わせ先
David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
+1-212-269-2834
info@dipexium.com
David Garrett
Vice President
Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
+1-212-269-2834
info@dipexium.com
(c) 2016 Dipexium Pharmaceuticals, Inc.
ソース:Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals Announces Issuance of Locilex(R) Patent in Japan
PR63894
NEW YORK, Mar. 28, 2016 /PRNewswire=KYODO JBN/--
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical
company focused on the development and commercialization of Locilex(R)
(pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide,
today announced that the government of Japan has issued a Locilex patent. The
patent claims are directed to a novel formulation of Locilex, an antimicrobial
peptide formulated as a topical cream. The issued patent has an expiry date in
June 2033.
"We are delighted to receive a Locilex patent in Japan, the third largest
pharmaceuticals market in the world," stated David P. Luci, President & Chief
Executive Officer of Dipexium, "We anticipate the issuance of additional
Locilex patents in other major international markets which will allow us to
continue to establish commercial viability of Locilex throughout the world."
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical
company focused on the development and commercialization of Locilex(R)
(pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide.
Initially, Locilex is targeted for the treatment of mild infections of diabetic
foot ulcers. Based on a compilation of available clinical and microbiology
data, Locilex is also considered a promising product candidate to treat other
mild and moderate skin and skin structure infections, including infected
decubitus ulcers, infected burns, infected surgical wounds and nasal
colonization of methicillin-resistant staphylococcus aureus (MRSA).
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of
Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may
contain, among other things, certain "forward-looking statements" within the
meaning of the U.S. federal securities laws. Such forward-looking statements
involve significant risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans, objectives,
projections, expectations and intentions and other statements identified by
words such as "projects," "may," "will," "could," "would," "should,"
"believes," "expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are subject to
significant risks and uncertainties, including those detailed in the Company's
filings with the Securities and Exchange Commission and those that relate to
the Company's ability to leverage the expertise of employees and partners to
assist the Company in the execution of its strategy. Actual results (including,
without limitation, the timing for and results of the clinical trials and
proposed NDA submission for Locilex(R)) may differ significantly from those set
forth in the forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as
required by applicable law.
Company Contacts:
David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
+1-212-269-2834
info@dipexium.com;
David Garrett
Vice President
Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
+1-212-269-2834
info@dipexium.com
(c) 2016 Dipexium Pharmaceuticals, Inc. All rights reserved.
SOURCE: Dipexium Pharmaceuticals, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。